Table 1.
Demographic data, clinical characteristics, and immunosuppression of study patients
| Characteristics | No CAV (n = 25) | CAV (n = 25) |
|---|---|---|
| Age (y, mean ± SD) | 65.3 ± 7 | 66.6 ± 8 |
| Time from transplant (mo, mean ± SD) | 111.2 ± 30.3 | 125.3 ± 33.2 |
| Male sex (no.) | 19 (76%) | 22 (88%) |
| Diabetes mellitus (no.) | 4 (16%) | 4 (16%) |
| Hyperlipidemia (no.) | 18 (72%) | 17 (68%) |
| Etiology (no.) | ||
| Ischemic cardiomyopathy | 10 (40%) | 10 (40%) |
| Dilated cardiomyopathy | 15 (60%) | 15 (60%) |
| Acute cellular rejection (no.) | 2 (8%) | 1 (4%) |
| Panel-reactive antibody level at transplant (%) | 3.1 | 3.8 |
| Mean ischemia time at transplant (min, mean ± SD) | 175 ± 54 | 183 ± 51 |
| Cytomegalovirus serostatus (no.) | ||
| Donor positive | 14 (56%) | 15 (60%) |
| Recipient positive | 12 (48%) | 16 (64%) |
| Donor positive, recipient negative | 5 (20%) | 3 (12%) |
| Donor negative, recipient positive | 3 (12%) | 4 (16%) |
| Immunosuppression (no.) | ||
| Cyclosporine, mycophenolate mofetil, steroids | 9 (36%) | 12 (48%) |
| Cyclosporine, everolimus, steroids | 8 (32%) | 7 (28%) |
| Tacrolimus, mycophenolate mofetil, steroids | 8 (32%) | 6 (24%) |
Differences between groups not significant for all characteristics. CAV, Cardiac allograft vasculopathy.